Predictive Value Of Molecular Monitoring In Patients With Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia Treated With Imatinib

【Objective】To investigate the predictive value of BCR-ABLtranscription reduction in patients with chronic myeloid leukemia treatedwith imatinib.【Methods】Analysed molecular responses of65patients withchronic myeloid leukemia treated with imatinib after12and18months,and its influence to long-term prognosis.【Results】A median follow-up of65patients with chronic myeloidleukaemia was54months (12-103),46cases of men and19cases ofwomen, the median age is42. The results showed：（1）No one of patientswho Achieved CCyR and MMR after imatinib therapy for12monthsprogressed or dead during the follow-up period. Of patients whoachieved CCyR but no MMR,2patients progressed and dead, the2-,3-,4-,5-year progression-free survival (PFS) rate was100%,94.4%,85.7%,80.0%, respectively. While the overall survival (OS) rate was100%,100%,85.7%,80.0%, respectively. In the group of patients who do notachieve CCyR,2patients occurred disease progression and death, the2-,3-,4-,5-year PFS rate was80.0%,77.8%,71.4%,66.7%，respectively.While the OS was90.0%,77.8%,71.4%,66.7%，respectively. The2-year and3-year PFS rate were significantly different among the three group (P<0.05)， and the accumulative OS among three group issignificantly different (P<0.05).（2）None of Patients who receivedCCyR and MMR after imatinib therapy for18months progressed ordead，accumulate PFS and OS were100%.2patients of group whoachieved CCyR but no MMR progressed and dead, the2-,3-,4-,5-yearPFS rate was100%,92.9%,83.3%,75.0%, respectively. The OS ratewas100%,100%,83.3%,75.0%，respectively. While the2-,3-,4-,5-year PFS rate in the group of patients who did not achieved CCyR was77.8%,75.0%,66.7%,60.0%, respectively. And the OS rate was88.9%,75.0%,66.7%,60.0%, respectively. Differences of PFS and OS amongthe three group were significantly.【Conclusion】Patients with chronic myeloid leukemia treated withimatinib achieved MMR after12months and18months tends to have abetter PFS and OS than patients who did not achieve MMR,and theprognosis of both two groups were superior to patients who did notachieve CCyR.